Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

Last updated: April 13, 2026
Sponsor: Aerogen Pharma Limited
Overall Status: Active - Recruiting

Phase

3

Condition

Lung Injury

Respiratory Failure

Treatment

Control

Control/Sham

APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)

Clinical Study ID

NCT06776783
APC-AF-CLN-003
  • Ages 1-24
  • All Genders

Study Summary

This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Inborn at the study site's hospital (i.e., not transferred from another hospitalfollowing delivery)

  2. Gestational age at birth of 26 through 33 weeks PMA

  3. Birth weight appropriate for gestational age (AGA, weight 3rd to 97th percentile onFenton Growth Curve)

  4. Birth weight ≤ 2000 grams

  5. Post-natal age 1 to 24 hours at randomization

  6. On nCPAP or NIV for at least 30 minutes with RSS = 1.4 - 2.0 to maintain SpO2 90-95%at randomization. RSS is calculated as (nCPAP cm H2O) × (FiO2) or as (NIV meanairway pressure cm H2O) × (FiO2).

  7. FiO2 ≥ 0.24 at randomization

  8. nCPAP or mPaw ≥ 6 cm H2O at randomization

  9. Chest radiograph (CXR) or lung ultrasound compatible with RDS prior to randomization

Exclusion

Exclusion Criteria:

  1. On SiPAP®, RAM® cannula, or high flow nasal cannula (HFNC) (> 2 liters per minute [LPM]) at the time of randomization

  2. Prior instillation of surfactant

  3. Premature rupture of membranes (PROM) occurring > 14 days before birth

  4. Significant congenital/chromosomal anomaly (e.g., Pierre Robin syndrome, clinicallysignificant congenital heart disease, or trisomy)

  5. Pneumothorax

  6. Other etiologies of respiratory distress

  7. Enrollment in another interventional study with similar efficacy endpoints

  8. Apgar score at 5 min of 0-3

  9. Prior cardiopulmonary resuscitation (CPR) or epinephrine

  10. Base Deficit > 15 mEq/L on most recent arterial blood gas (not capillary blood gas,venous blood gas, or cord gas) prior to randomization. Note that arterial blood gasis not required prior to randomization.

  11. Partial pressure of carbon dioxide (PaCO2) > 65 mmHg on most recent arterial bloodgas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization.

  12. Triplet or higher order multiple birth

Study Design

Total Participants: 520
Treatment Group(s): 4
Primary Treatment: Control
Phase: 3
Study Start date:
September 24, 2025
Estimated Completion Date:
May 31, 2029

Connect with a study center

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas 72205
    United States

    Active - Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock 4119403, Arkansas 4099753 72205
    United States

    Site Not Available

  • Jacobs Medical Center

    La Jolla, California 92037
    United States

    Active - Recruiting

  • UF Health Jacksonville

    Jacksonville, Florida 32209
    United States

    Active - Recruiting

  • Advent Health

    Orlando, Florida 32803
    United States

    Active - Recruiting

  • UF Health Jacksonville

    Jacksonville 4160021, Florida 4155751 32209
    United States

    Site Not Available

  • Advent Health

    Orlando 4167147, Florida 4155751 32803
    United States

    Site Not Available

  • Memorial Hospital of South Bend

    South Bend, Indiana 46601
    United States

    Active - Recruiting

  • Memorial Hospital of South Bend

    South Bend 4926563, Indiana 4921868 46601
    United States

    Site Not Available

  • Goryeb Children's Hospital

    Morristown, New Jersey 07960
    United States

    Active - Recruiting

  • Goryeb Children's Hospital

    Morristown 5101427, New Jersey 5101760 07960
    United States

    Site Not Available

  • The Trustees of Columbia University in the City of New York

    New York, New York 10032
    United States

    Active - Recruiting

  • Montefiore Medical Center

    The Bronx, New York 10461
    United States

    Active - Recruiting

  • Maria Farreri Children's Hospital

    Valhalla, New York 10595
    United States

    Active - Recruiting

  • Montefiore Medical Center

    The Bronx 5110266, New York 5128638 10461
    United States

    Site Not Available

  • Christus Children's Hospital

    San Antonio, Texas 78207
    United States

    Active - Recruiting

  • Christus Children's Hospital

    San Antonio 4726206, Texas 4736286 78207
    United States

    Site Not Available

  • University of Virginia School of Medicine

    Charlottesville, Virginia 22903
    United States

    Active - Recruiting

  • University of Virginia School of Medicine

    Charlottesville 4752031, Virginia 6254928 22903
    United States

    Site Not Available

  • WVU Medicine Children's Hospital

    Morgantown, West Virginia 26506
    United States

    Active - Recruiting

  • WVU Medicine Children's Hospital

    Morgantown 4815352, West Virginia 4826850 26506
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.